Leerink Partners analyst Faisal Khurshid has reiterated their bullish stance on KYMR stock, giving a Buy rating on March 3.
Faisal Khurshid has given his Buy rating due to a combination of factors surrounding Kymera Therapeutics’ promising developments in STAT6 targeting therapies. The company is leading in the competitive landscape with its STAT6 degrader, KT-621, which is expected to show significant target degradation in upcoming human trials. The anticipation of over 90% STAT6 target degradation, coupled with a safety profile comparable to Dupixent, positions KT-621 as a strong candidate for success.
Furthermore, Kymera’s preclinical data supports the potential for robust and selective degradation of STAT6, with previous programs demonstrating high translatability from animal models to human trials. The company’s experience with similar programs and the strategic importance of STAT6 degradation in both blood and skin further bolster confidence in the potential outcomes. These factors collectively contribute to Khurshid’s optimistic outlook and Buy rating for Kymera Therapeutics.
According to TipRanks, Khurshid is a 5-star analyst with an average return of 31.2% and a 43.86% success rate. Khurshid covers the Healthcare sector, focusing on stocks such as Geron, Pliant Therapeutics, and Kymera Therapeutics.
In another report released on March 3, Stifel Nicolaus also maintained a Buy rating on the stock with a $51.00 price target.
Questions or Comments about the article? Write to editor@tipranks.com